Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6) ; volume:18 ; number:5 ; day:24 ; month:7 ; year:2023 ; pages:749-765 ; date:9.2023
Targeted oncology ; 18, Heft 5 (24.7.2023), 749-765, 9.2023
- Urheber
-
Witte, Hanno M.
Riedl, Jörg
Künstner, Axel
Fähnrich, Anke
Ketzer, Julius
Fliedner, Stephanie M. J.
Reimer, Niklas
Bernard, Veronica
Bubnoff, Nikolas von
Merz, Hartmut
Busch, Hauke
Feller, Alfred
Gebauer, Niklas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-023-00983-5
- URN
-
urn:nbn:de:101:1-2023121213084721003269
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Witte, Hanno M.
- Riedl, Jörg
- Künstner, Axel
- Fähnrich, Anke
- Ketzer, Julius
- Fliedner, Stephanie M. J.
- Reimer, Niklas
- Bernard, Veronica
- Bubnoff, Nikolas von
- Merz, Hartmut
- Busch, Hauke
- Feller, Alfred
- Gebauer, Niklas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements
Molecularly distinct models of zebrafish Myc-induced B cell leukemia
MYC
MYC
MYC
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements
Molecularly distinct models of zebrafish Myc-induced B cell leukemia
MYC
MYC
MYC
Targeted inhibition of DHODH is synergistic with BCL2 blockade in HGBCL with concurrent MYC and BCL2 rearrangement
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
B-lymphoblastic leukemia/lymphoma with MYC and BCL2 gene rearrangements shows evidence for clonal evolution and mitotic recombination
Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements
Molecularly distinct models of zebrafish Myc-induced B cell leukemia
MYC
MYC
MYC